(Sharecast News) - Pharma group GSK has announced that US regulators have approved for use its Nucala treatment for adults with chronic obstructive pulmonary disease (COPD) following positive results from phase III trials.
The US Food and Drug Administration has given the green light to Nucala, otherwise known as mepolizumab, as...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE